Community level programs were effective and can be expanded to help reduce colorectal cancer disparities, according to a study by National Cancer Institute researchers.
A recent study found that the cost of cancer care in the United States, which was estimated at $183 billion in 2015, is projected to exceed $245 billion by 2030, an increase of more than 30 percent.
The American Cancer Society issues guidelines for diet and physical activity, and more cancer news of the week from Cancer Today.
Immune checkpoint inhibitors kill cancer cells by releasing the brakes on the immune system, thereby allowing it to mount an antitumor response. This form of immunotherapy has led to dramatic responses in some patients; however, most patients’ tumors do not respond to immune checkpoint inhibition, and resistance can develop in tumors that initially respond.
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with a common form of esophageal cancer.
The vast majority of participants enrolled in nearly 60 prostate cancer clinical trials were non-Hispanic white men, Harvard researchers report.
A recent study reports that high adherence to oral diabetes medication was associated with improved survival for patients with colorectal cancer.
Some people with early-stage non-small cell lung cancer can benefit significantly from treatment with a targeted therapy, and more news of the week from Cancer Today.
A recent study shows that testicular cancer rates are increasing for Asian/Pacific Islanders, Hispanics, and American Indians/Alaska Natives.
In the early 1990s, Gregg Semenza, MD, PhD, was a postdoctoral researcher studying the cellular response to reduced oxygen levels, a state known as hypoxia. His focus was on the erythropoietin gene, EPO, which controls red blood cell production, and thus oxygen delivery. After identifying a sequence within the EPO gene that was critical for the response to hypoxia, Semenza isolated a mystery protein that was bound to this sequence.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More